½ÃÀ庸°í¼­
»óǰÄÚµå
1268846

¼¼°èÀÇ ¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м®, ¸®Æ÷Æ®, Á¦Ç°º°(Äݶó°Õ&PMMA ¸¶ÀÌÅ©·Î ½ºÇǾî, º¸Åø¸®´®½ºÅ² AÇü), ÃÖÁ¾ ¿ëµµº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹® µ¿Çâ(2023-2030³â)

Facial Injectable Market Size, Share & Trends Analysis Report By Product (Collagen & PMMA Microspheres, Botulinum Toxin Type A), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 172 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ ¾ó±¼¿ë ÁÖÀÔÁ¦(Facial Injectable) ½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2030³â±îÁö 10.3%ÀÇ CAGR ±Ô¸ð·Î È®´ëµÇ¾î 2030³â 276¾ï ´Þ·¯ ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾ó±¼¿ë ÁÖÀÔÁ¦´Â ÁÖ¸§À» ÁÙÀÌ°í ¾ó±¼ º¼·ý°ú ÆØÃ¢À» ȸº¹ÇÏ´Â µ¥ »ç¿ëµÇ´Â ¹°ÁúÀÔ´Ï´Ù. ¾ó±¼ ÇǺΠǥ¸é ¾Æ·¡¿¡ ÁÖÀԵ˴ϴÙ. ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ¾ó±¼¿ë ÁÖÀÔÁ¦´Â È÷¾Ë·ç·Ð»ê, º¸Åø¸®´® µ¶¼Ò À¯Çü A, ÁßÇÕü ÃæÀüÁ¦ µîÀÌ Æ÷ÇԵ˴ϴÙ.

ƯÈ÷ ½ÅÈï±¹Àº ¿Ü¸ð¸¦ °ü¸®ÇÏ´Â °æÇâÀÌ °­ÇØÁö°í ÀÖ´Â °ÍÀÌ ½ÃÀåÀ» °ßÀÎÇÏ´Â Áß¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ Àúħ½À ¼ö¼ú ¼ÒºñÀÚ ¼±È£µµ º¯È­µµ ½ÃÀå ¼ºÀåÀ» Áö¿øÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¹Ì±¹ ¼ºÇü¿Ü°úÇÐȸ(ASPS)¿¡ µû¸£¸é, 2020³â ¹Ì±¹ ½Ç½ÃµÈ Àúħ½À ¼ö¼ú Åé 5¿¡ º¸Åø¸®´®½ºÅ² A¿Í ¿¬Á¶Á÷ ÇÊ·¯°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. µû¶ó¼­ ¾ó±¼¿ë ÁÖÀÔÁ¦´Â ÇâÈÄ ¸î ³â°£ µ¿¾È ³ôÀº ¼ºÀå Àü¸ÁÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ªÀº ½ÃÀå ³ôÀº ¼öÀÍ¿øÀÌ µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ÀÌ Áö¿ªÀº Àεµ¿Í °°Àº ±¹°¡µé¿¡ ÀÇÇØ Áö¿øµÇ°í ÀÖÀ¸¸ç, ¿Ü¸ð °ü½É Áõ°¡°¡ ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¶ÇÇÑ °¡Ã³ºÐ¼Òµæ Áõ°¡¸¦ ¹è°æÀ¸·Î Áß°£¼ÒµæÃþÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Allergan»ç µî ±â¾÷µµ ÀÌ ³ª¶ó¿¡¼­ Á¸À縦 È®´ëÇÏ¿´½À´Ï´Ù.

À¯Çà ¹ß»ýÀ¸·Î 2020³â 1ºÐ±â¿Í 2ºÐ±â¿¡´Â ºñ¼ö¼ú ¹× ¹Ì¿ë ¼ºÇü ¼ö¼úÀÌ º¸·ùµÇ¾ú½À´Ï´Ù. ±×·¯³ª Èı⿡´Â °¡Ã³ºÐ ¼Òµæ Áõ°¡·Î ȯÀÚ°¡ ÀÌÀüº¸´Ù ´õ ¹Ì¿ë Ä¡·á¸¦ ¹Þ±â¸¦ ¿øÇ߱⠶§¹®¿¡ ¹Ì¿ë »ó´ã°ú ½Ã¼ú ³ôÀº ¼ö¿ä°¡ º¸¿´½À´Ï´Ù. °Ô´Ù°¡ ¿Â¶óÀÎ ºñµð¿À Ç÷§Æû°ú Àü¹®ÀûÀΠȸÀÇ, ¸Å·ÂÀûÀ¸·Î º¸ÀÌ°í ½ÍÀº ¼Ò¸Á µî »õ·Î¿î Æ´»õ ÃËÁø ¿äÀεµ °è¼Ó ¼ºÀåÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù.

¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • º¸Åø¸®´® µ¶¼Ò AÇüÀÌ ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â °¡Àå ÀαâÀÖ´Â Àúħ½À ¼ö¼ú Áß ÇϳªÀÔ´Ï´Ù.
  • ¾ó±¼ ÁÖ¸§ Ä¡·á µî ¹Ì¿ëÀ» À§ÇÑ ¾È¸é ÁÖ»ç ÀÌ¿ëÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡, ÆäÀ̽º¶óÀÎ ¼öÁ¤ ºÐ¾ß´Â ¿¹Ãø ±â°£ Áß ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • ºÏ¹Ì´Â Á¦Ç° ÀÔ¼ö°¡ ¿ëÀÌÇÏ¿© ¼÷·ÃµÈ ¿Ü°úÀǻ簡 ´Ù¼ö Á¸ÀçÇϱ⠶§¹®¿¡ 42.1%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

  • ½ÃÀå ¼¼ºÐÈ­ ¹× ¹üÀ§
  • Á¶»ç ¹æ¹ý
  • Á¤º¸ Á¶´Þ
    • ±¸ÀÔÇÑ µ¥ÀÌÅͺ£À̽º
    • GVR ³»ºÎ µ¥ÀÌÅͺ£À̽º
    • 2Â÷ Á¤º¸
    • 1Â÷ Á¶»ç
  • Á¤º¸ ¶Ç´Â µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ ºÐ¼® ¸ðÇü
  • ½ÃÀå Çü¼º°ú °ËÁõ
  • ¸ðÇü »ó¼¼
    • »óǰ Ç÷οì ÇØ¼®(¸ðÇü 1)
      • Á¢±Ù 1 : »óǰ È帧 Á¢±Ù
  • 2Â÷ Á¤º¸ ¸®½ºÆ®
  • 1Â÷ Á¤º¸ ¸ñ·Ï
  • ¸ñÀû

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå Àü¸Á
  • ºÎ¹® Àü¸Á

Á¦3Àå ¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • ºÎ¸ð ½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø ¿äÀÎ ºÐ¼®
    • ½ÃÀå ¾ïÁ¦ ¿äÀÎ ºÐ¼®
  • ¾ó±¼¿ë ÁÖÀÔÁ¦ : ½ÃÀå ºÐ¼® µµ±¸
    • ¾÷°è ºÐ¼®-Æ÷ÅÍÀÇ 5¼¼·Â
      • °ø±ÞÀÚ ÆÄ¿ö
      • ±¸¸ÅÀÚ Çù»ó·Â
      • ´ëü À§Çù
      • ½Å±Ô Âü°¡ÀÚ À§Çù
      • °æÀï ±â¾÷ °£ Àû´ë °ü°è
    • PESTEl ºÐ¼®
      • Á¤Ä¡Àû »óȲ
      • ȯ°æ »óȲ
      • »çȸÀû »óȲ
      • ±â¼ú »óȲ
      • ¹ýÀû »óȲ
    • ÁÖ¿ä °Å·¡¿Í Àü·« Á¦ÈÞ ºÐ¼®

Á¦4Àå ¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå : Á¦Ç°º° ºÎ¹® ºÐ¼®(2018-2030³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • Á¦Ç° ½ÃÀå Á¡À¯À² ºÐ¼®(2022-2030³â)
  • ¼¼°èÀÇ ¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå, Á¦Ç°º°(2018-2030³â)
  • ÀÌÇÏ ½ÃÀå : ±Ô¸ð, ¿¹Ãø ¹× °æÇ⠺м®(2018-2030³â)
    • Äݶó°Õ°ú PMMA
    • È÷¾Ë·ç·Ð»ê(HA)
    • AÇü º¸Åø¸®´® µ¶¼Ò
    • Ä®½· È÷µå·Ï½Ç ¾ÆÆÄŸÀÌÆ®(CaHA)
    • Æú¸®-l-¶ôÆ®»ê(PllA)
    • ±âŸ

Á¦5Àå ¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå : ¾ÖÇø®ÄÉÀ̼Ǻ° ºÎ¹® ºÐ¼®(2018-2030³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • Ä«Å×°í¸® ½ÃÀå Á¡À¯À² ºÐ¼®(2022-2030³â)
  • ¼¼°èÀÇ ¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå, ¿ëµµº°(2018-2030³â)
  • ÀÌÇÏ ½ÃÀå : ±Ô¸ð, ¿¹Ãø ¹× °æÇ⠺м®(2018-2030³â)
    • ÆäÀ̽º ¶óÀÎ º¸Á¤
    • ÀÔ¼ú È®´ë¼ú
    • ÆäÀ̽º ¸®ÇÁÆ®
    • ¿©µå¸§ ÀÚÃë Ä¡·á
    • Áö¹æ À§ÃàÁõ Ä¡·á
    • ±âŸ

Á¦6Àå ¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå : ºÎ¹® ºÐ¼®, ÃÖÁ¾ »ç¿ëÀÚº°(2018-2030³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • Ä«Å×°í¸® ½ÃÀå Á¡À¯À² ºÐ¼®(2022-2030³â)
  • ¼¼°èÀÇ ¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå, ÃÖÁ¾ »ç¿ëÀÚº°(2018-2030³â)
  • ÀÌÇÏ ½ÃÀå : ±Ô¸ð, ¿¹Ãø ¹× °æÇ⠺м®(2018-2030³â)
    • ¸Þµå ½ºÆÄ
    • ÇǺΰú Ŭ¸®´Ð
    • º´¿ø

Á¦7Àå ¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå :Áö¿ª ½ÃÀå ºÐ¼®, Áö¿ªº°(2018-2030³â)

  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • Áö¿ª ½ÃÀå Á¡À¯À² ºÐ¼®(2022-2030³â)
  • 2018³âºÎÅÍ 2030³â ½ÃÀå : ±Ô¸ð, ¿¹Ãø, Æ®·»µå ºÐ¼®:
  • ºÏ¹Ì
    • ±¹°¡º°(2018-2030³â)
    • Á¦Ç°º°(2018-2030³â)
    • ¿ëµµº°(2018-2030³â)
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ±¹°¡º°(2018-2030³â)
    • Á¦Ç°º°(2018-2030³â)
    • ¿ëµµº°(2018-2030³â)
    • ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ª
    • ±¹°¡º°(2018-2030³â)
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ±¹°¡º°(2018-2030³â)
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿°ú ¾ÆÇÁ¸®Ä«
    • ±¹°¡º°(2018-2030³â)
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ® ¿¬¹æ
    • Äí¿þÀÌÆ®

Á¦8Àå ¾ó±¼¿ë ÁÖÀÔÁ¦ ½ÃÀå-°æÀï ºÐ¼®

  • Key companies profiLED
    • Allergan
      • ȸ»ç ÁÖ¿ä ¿ä¾à
      • À繫½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å©
      • ÆÇ¸Å Àü·«
    • Ipsen
      • ȸ»ç ÁÖ¿ä ¿ä¾à
      • À繫½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å©
      • ÆÇ¸Å Àü·«
    • Merz Pharma GmbH&Co. KGaA
      • ȸ»ç ÁÖ¿ä ¿ä¾à
      • À繫½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å©
      • ÆÇ¸Å Àü·«
    • Suneva Medical, Inc.
      • ȸ»ç ÁÖ¿ä ¿ä¾à
      • À繫½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å©
      • ÆÇ¸Å Àü·«
    • Sinclair Pharma
      • ȸ»ç ÁÖ¿ä ¿ä¾à
      • À繫½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å©
      • ÆÇ¸Å Àü·«
    • Bloomage BioTechnology
      • ȸ»ç ÁÖ¿ä ¿ä¾à
      • À繫½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å©
      • ÆÇ¸Å Àü·«
    • Anika Therapeutics, Inc.
      • ȸ»ç ÁÖ¿ä ¿ä¾à
      • À繫½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å©
      • ÆÇ¸Å Àü·«
    • Prollenium Medical Technologies Inc.
      • ȸ»ç ÁÖ¿ä ¿ä¾à
      • À繫½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å©
      • ÆÇ¸Å Àü·«
    • . Galderma SA
      • ȸ»ç ÁÖ¿ä ¿ä¾à
      • À繫½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å©
      • ÆÇ¸Å Àü·«
    • Medytox
      • ȸ»ç ÁÖ¿ä ¿ä¾à
      • À繫½ÇÀû
      • Á¦Ç° º¥Ä¡¸¶Å©
      • ÆÇ¸Å Àü·«
NJH 23.05.30

Facial Injectable Market Growth & Trends:

The global facial injectable market size is expected to reach USD 27.6 billion by 2030, expanding at 10.3% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc.The facial injectable is a substance that is used to reduce wrinkles and restore volume & fullness in the face. It is injected beneath the facial skin surface. Some commonly used facial injectables include hyaluronic acid, botulinum toxin type A, and polymer fillers.

Growing focus on physical appearance, especially in developing countries is one of the key factors expected to drive the market. In addition, a shift in consumer preference towards minimally invasive procedures is also expected to support market growth. According to the American Society of Plastic Surgeons (ASPS), in 2020, botulinum toxin A and soft tissue fillers were among the top 5 minimally invasive procedures carried out in the U.S. Thus, facial injectable holds high growth prospects in the years to come.

Asia Pacific region is expected to become a high-revenue generator in the global market. The region is backed by countries such as India, where a growing focus on physical appearance is expected to create a lucrative opportunity in the market. Companies such as Allergan are also expanding their presence in the country owing to the rise in the middle-class population backed by increasing disposable income.

The onset of the pandemic led to non-surgical and cosmetic surgeries being put on hold in the first and second quarters of 2020. However, the later months witnessed high demand for aesthetic consultations and procedures as patients were willing to undergo cosmetic treatments now more than ever due to high disposable income. Furthermore, new niche drivers such as a desire to look appealing on online video platforms and professional meetings also continue to drive growth.

Facial Injectable Market Report Highlights:

  • The botulinum toxin type A segment is projected to dominate the market throughout the forecast period. It is one of the most popular minimally invasive procedures
  • The facial line correction segment is projected to grow rapidly over the forecast period owing to the rise in the use of facial injectables for aesthetic procedures such as the treatment of wrinkles on the face
  • North America dominated the market with a revenue share of 42.1% owing to the easy availability of the products and the presence of a large number of skilled surgeons

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1: Understanding the market dynamics
    • 1.9.2. Objective 2: Understanding the market estimates and forecasts
    • 1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
    • 1.9.4. Objective 4: Understanding the key product and application scopes to conclude the market size

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook

Chapter 3. Facial Injectable Market Variables, Trends & Scope

  • 3.1. Market Lineage outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Facial injectable: Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat from new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Environmental Landscape
      • 3.3.2.3. Social Landscape
      • 3.3.2.4. Technology Landscape
      • 3.3.2.5. Legal Landscape
    • 3.3.3. Major Deals & Strategic Alliances Analysis

Chapter 4. Facial Injectable Market: Segment Analysis, By Product, 2018 - 2030 (USD Million)

  • 4.1. Segment Dashboard
  • 4.2. Product Market Share Analysis, 2022 & 2030
  • 4.3. Global Facial Injectable Market, by Product, 2018 to 2030
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Collagen & PMMA
    • 4.4.2. Hyaluronic Acid (HA)
    • 4.4.3. Botulinum Toxin Type A
    • 4.4.4. Calcium Hydroxylapatite (CaHA)
    • 4.4.5. Poly-L-Lactic Acid (PLLA)
    • 4.4.6. Others

Chapter 5. Facial Injectable Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 5.1. Segment Dashboard
  • 5.2. Category Market Share Analysis, 2022 & 2030
  • 5.3. Global Facial Injectable Market, by Application, 2018 to 2030
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Facial Line Correction
    • 5.4.2. Lip Augmentation
    • 5.4.3. Face Lift
    • 5.4.4. Acne Scar Treatment
    • 5.4.5. Lipoatrophy Treatment
    • 5.4.6. Others

Chapter 6. Facial Injectable Market: Segment Analysis, By End-use, 2018 - 2030 (USD Million)

  • 6.1. Segment Dashboard
  • 6.2. Category Market Share Analysis, 2022 & 2030
  • 6.3. Global Facial Injectable Market, by End-Use, 2018 to 2030
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. MedSpa
    • 6.4.2. Dermatology Clinics
    • 6.4.3. Hospitals

Chapter 7. Facial Injectable Market: Regional Market Analysis, By Region, 2018 - 2030 (USD Million)

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2022 & 2030
  • 7.3. Market Size, & Forecasts, and Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market estimates and forecast, by country, 2018 - 2030 (USD Million)
    • 7.4.2. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
    • 7.4.3. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
    • 7.4.4. U.S.
      • 7.4.4.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.4.4.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.4.4.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.4.5. Canada
      • 7.4.5.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.4.5.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million
      • 7.4.5.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market estimates and forecast, by country, 2018 - 2030 (USD Million)
    • 7.5.2. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
    • 7.5.3. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
    • 7.5.4. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.5.5. Germany
      • 7.5.5.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.5.5.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.5.5.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.5.6. U.K.
      • 7.5.6.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.5.6.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.5.6.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.5.7. France
      • 7.5.7.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.5.7.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.5.7.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.5.8. Italy
      • 7.5.8.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.5.8.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.5.8.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.5.9. Spain
      • 7.5.9.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.5.9.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.5.9.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.5.10. Sweden
      • 7.5.10.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.5.10.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.5.10.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.5.11. Norway
      • 7.5.11.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.5.11.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.5.11.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.5.12. Denmark
      • 7.5.12.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.5.12.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.5.12.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market estimates and forecast, by country, 2018 - 2030 (USD Million)
      • 7.6.1.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.6.1.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.6.1.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.6.2.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.6.2.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.6.3.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.6.3.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.6.4.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.6.4.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.6.5.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.6.5.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.6.6.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.6.6.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market estimates and forecast, by country, 2018 - 2030 (USD Billion)
      • 7.7.1.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.7.1.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.7.2.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
    • 7.7.3. Mexico
      • 7.7.3.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.7.3.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
    • 7.7.4. Argentina
      • 7.7.4.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.7.4.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Market estimates and forecast, by country, 2018 - 2030 (USD Billion)
      • 7.8.1.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.8.1.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.8.2.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.8.3.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.8.4.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Market estimates and forecast, by product, 2018 - 2030 (USD Million)
      • 7.8.5.2. Market estimates and forecast, by application, 2018 - 2030 (USD Million)
      • 7.8.5.3. Market estimates and forecast, by End-use, 2018 - 2030 (USD Million)

Chapter 8. Facial Injectable Market - Competitive Analysis

  • 8.1. Key companies profiled
    • 8.1.1. Allergan
      • 8.1.1.1. Company Overview
      • 8.1.1.2. Financial Performance
      • 8.1.1.3. Product Benchmarking
      • 8.1.1.4. Strategic Initiatives
    • 8.1.2. Ipsen
      • 8.1.2.1. Company Overview
      • 8.1.2.2. Financial Performance
      • 8.1.2.3. Product Benchmarking
      • 8.1.2.4. Strategic Initiatives
    • 8.1.3. Merz Pharma GmbH & Co. KGaA
      • 8.1.3.1. Company Overview
      • 8.1.3.2. Financial Performance
      • 8.1.3.3. Product Benchmarking
      • 8.1.3.4. Strategic Initiatives
    • 8.1.4. Suneva Medical, Inc.
      • 8.1.4.1. Company Overview
      • 8.1.4.2. Financial Performance
      • 8.1.4.3. Product Benchmarking
      • 8.1.4.4. Strategic Initiatives
    • 8.1.5. Sinclair Pharma
      • 8.1.5.1. Company Overview
      • 8.1.5.2. Financial Performance
      • 8.1.5.3. Product Benchmarking
      • 8.1.5.4. Strategic Initiatives
    • 8.1.6. Bloomage BioTechnology
      • 8.1.6.1. Company Overview
      • 8.1.6.2. Financial Performance
      • 8.1.6.3. Product Benchmarking
      • 8.1.6.4. Strategic Initiatives
    • 8.1.7. Anika Therapeutics, Inc.
      • 8.1.7.1. Company Overview
      • 8.1.7.2. Financial Performance
      • 8.1.7.3. Product Benchmarking
      • 8.1.7.4. Strategic Initiatives
    • 8.1.8. Prollenium Medical Technologies Inc.
      • 8.1.8.1. Company Overview
      • 8.1.8.2. Financial Performance
      • 8.1.8.3. Product Benchmarking
      • 8.1.8.4. Strategic Initiatives
    • 8.1.9. . Galderma S.A.
      • 8.1.9.1. Company Overview
      • 8.1.9.2. Financial Performance
      • 8.1.9.3. Product Benchmarking
      • 8.1.9.4. Strategic Initiatives
    • 8.1.10. Medytox
      • 8.1.10.1. Company Overview
      • 8.1.10.2. Financial Performance
      • 8.1.10.3. Product Benchmarking
      • 8.1.10.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦